Upcoming Event: SITC 2026 x KACTUS

KACTUS is excited to join the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place November 4–8, 2026 at the Phoenix Convention Center in Phoenix, Arizona. Now in its 41st year, SITC’s Annual Meeting brings together researchers, clinicians, industry professionals, regulators, and other leaders from around the world to share the latest advances in cancer immunotherapy and tumor immunology.

The 2026 meeting will combine pre-conference programming with three days of Annual Meeting sessions, offering opportunities to explore cutting-edge basic, translational, and clinical research, oral and poster abstracts, emerging technologies, and new approaches to improving cancer patient outcomes.

What is SITC?

The Society for Immunotherapy of Cancer (SITC) is a member-driven professional organization dedicated to improving cancer patient outcomes by advancing the science, development, and application of cancer immunology and immunotherapy.

SITC brings together basic and translational scientists, clinicians, healthcare professionals, government and regulatory leaders, and industry professionals to encourage scientific exchange, collaboration, education, and innovation across the immuno-oncology community. Its Annual Meeting is one of the field’s leading forums for sharing new research, discussing clinical advances, and exploring the technologies and therapeutic strategies shaping the future of cancer immunotherapy.

Event Overview

Venue: Phoenix Convention Center, 100 N 3rd Street, Phoenix, AZ 85004

Pre-Conference Day 1: Wednesday, November 4, 2026 | Programme Hours: 2:00–5:00 PM MT
Pre-Conference Day 2: Thursday, November 5, 2026 | Programme Hours: 8:00 AM–9:30 PM MT
Conference Day 1: Friday, November 6, 2026 | Programme Hours: 6:45 AM–7:00 PM MT

Exhibit Hall Hours: 10:00 AM–2:00 PM & 5:00–7:00 PM MT

Conference Day 2: Saturday, November 7, 2026 | Programme Hours: 8:25 AM–11:55 PM MT

Exhibit Hall Hours: 10:00 AM–2:00 PM & 6:00–8:10 PM MT

Conference Day 3: Sunday, November 8, 2026 | Programme Hours: 7:40 AM–1:00 PM MT

No Exhibit Hall

KACTUS Booth #522

Event Schedule

The SITC 2026 Annual Meeting will take place November 6–8 following two days of pre-conference programming on November 4–5. The meeting will bring together the cancer immunotherapy community for scientific presentations, oral and rapid oral abstracts, poster sessions, exhibits, networking, and discussions spanning basic, translational, and clinical immuno-oncology research.

Day 1 – November 6, 2026

Presidential Welcome: 8:00–8:05 AM
Awards Ceremony 1: 8:05–8:35 AM
Richard V. Smalley Memorial Award and Lectureship: 8:35–9:10 AM
Thomas Waldmann Memorial Plenary Session: Cancer Vaccines, Current and Future: 9:40–11:30 AM
Clinical Oral Abstract Session: 11:30 AM–12:15 PM
Exhibits and Poster Viewing 1: 12:15–1:45 PM
Rapid Oral – Basic 1 and Clinical 1: 12:30–1:30 PM
Concurrent Sessions 106a–106e: 1:45–3:25 PM
Concurrent Sessions 107a–107e: 3:55–5:30 PM
Exhibits and Poster Viewing 2: 5:30–7:00 PM

Day 2 – November 7, 2026

Organizer Welcome: 8:25–8:30 AM
Keynote Address: 8:30–9:05 AM
Spatial Biology: 9:35–11:15 AM
Hot Topic Symposium: External Factors Contributing to Immunotherapy Response: 11:15 AM–12:15 PM
Exhibits, Poster Viewing and JITC Meet the Editor: 12:15–1:45 PM
Rapid Oral – Basic 2 and Clinical 2: 12:30–1:30 PM
Clinical Oral Abstract Session 2: 1:45–3:00 PM
Concurrent Sessions 206a–206e: 3:30–4:50 PM
Concurrent Sessions 207a–207e: 5:20–6:40 PM
Exhibits and Poster Viewing 3: 6:40–8:10 PM
The CheckPoints Party: 8:30–11:55 PM

Day 3 – November 8, 2026

Business Meeting: 7:40–8:10 AM
Organizer Welcome: 8:10–8:15 AM
Presidential Session: 8:15–9:40 AM
CRI William B. Coley Award Lecture: 9:55–10:30 AM
Session 303: COOPERATIVE BINDING: The bi-specific VEGF/PD(L)-1 Inhibitor Approach to cancer immunotherapy: Savior or Pretender?: 10:45 AM–12:25 PM
Awards Ceremony 2: 12:30–1:00 PM

About KACTUS

KACTUS excels in crafting and producing an array of superior-grade, highly active recombinant proteins and enzymes, catering to diverse sectors like antibody drug discovery, immunotherapy, gene therapy, and mRNA therapeutics. Our expansive catalog, boasting over 3,000 recombinant proteins, encompasses a wide spectrum of targets, species, tags, and labels, each thoughtfully chosen to address the specific, unmet needs of scientists engaged in drug development. The hallmark of our product selection process is a rigorous emphasis on exceptional quality and a steadfast commitment to ensuring reliable supply, thereby upholding the highest standards of excellence and client satisfaction.